

**Bibliography**  
**Advisory Committee for Pharmaceutical Science**  
**October 19-20, 2004**

**Day 1: Tuesday, October 19, 2004**

**Critical Path Initiative -- Challenges and Opportunities**

1. "Challenge and Opportunity on the Critical Path to New Medical Products". FDA white paper available on the FDA Website:  
<http://www.fda.gov/oc/initiatives/criticalpath/>
2. Bush, Laura, "From CGMPs to the Critical Path -- FDA Focuses on Innovation, Quality, and Continuous Improvement—Inside and Out", *Pharmaceutical Technology*, July 2004, p. 34-44. [Reprinted by permission of the author]

**Day 2: Wednesday, October 20, 2004**

**"Desired State" -- OPS Moving Forward**

1. "Pharmaceutical cGMPs for the 21<sup>st</sup> Century -- A Risk-based Approach Final Report". FDA report available on the FDA Website:  
[http://www.fda.gov/cder/gmp/gmp2004/GMP\\_finalreport2004.htm](http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm)
2. "Innovation and Continuous Improvement in Pharmaceutical Manufacturing". FDA report available on the FDA Website:  
<http://www.fda.gov/cder/gmp/gmp2004/manufSciWP.pdf>
3. Leuenberger, H., Lanz, M, "Pharmaceutical Powder Technology – from Art to Science: the challenge of FDA's PAT initiative", *Advanced Powder Technology*, Volume 16, No.1, February 2005 (in press). [Not yet published -- preprint copy provided by permission] of the Chief Editor]

**Bioequivalence of Generic Drugs**

1. Hayes, S. N., Dunne, A., Smart, T., Davis, J., "Interpretation and Optimization of the Dissolution Specifications for a Modified Release Product with an In Vivo–In Vitro Correlation (IVIVC)", *Journal of Pharmaceutical Sciences*, Vo. 93, No.3, March 2004, p. 571-581.